Background Human cancers consume larger amounts of glucose compared to normal
tissues with most being converted and excreted as lactate despite abundant oxygen …

Background Imatinib-resistant chronic myeloid leukemia (CML) patients receiving second-
line tyrosine kinase inhibitor (TKI) therapy with dasatinib or nilotinib have a higher risk of …

Tyrosine kinase inhibitors such as imatinib mesylate have changed the clinical course of
chronic myeloid leukemia; however, the observation that these inhibitors do not target the …

Mena [mammalian Ena (Enabled)]/VASP (vasodilator-stimulated phosphoprotein) proteins
are the homologues of Drosophila Ena. In Drosophila, Ena is a substrate of the tyrosine …

The deregulated kinase activity of p210-BCR/ABL oncoproteins, hallmark of chronic
myelogenous leukaemia (CML), induces and sustains the leukaemic phenotype, and …

Chronic myeloid leukemia (CML) is a cancer of the hematopoietic system initiated by a
single genetic mutation which results in the oncogenic fusion protein Bcr-Abl. Untreated …

Abstract In Chronic Myeloid Leukemia, the transition from drug sensitive to drug resistant
disease is poorly understood. Here, we used exploratory sequencing of gene transcripts to …

Chronic myeloid leukaemia (CML) is driven by the fusion protein Bcr-Abl, a constitutively
active tyrosine kinase playing a crucial role in initiation and maintenance of CML phenotype …

Chronic myeloid leukemia (CML) was considered for a long time one of the most hostile
leukemia that was incurable for most of the patients, predominantly due to the extreme …

Chronic myeloid leukemia (CML) is a myeloproliferative disease with a characteristic BCR-
ABL tyrosine kinase (TK) fusion protein. Despite the clinical efficacy accomplished by TKIs …